Price competition in the US insulin market is heating up; Novo Nordisk reported in its second-quarter earnings call that its 2018 US insulin prices could drop below 2017 levels.
Price competition in the US insulin market is heating up; Novo Nordisk reported in its second-quarter earnings call that its 2018 US insulin prices could drop below 2017 levels.
The Danish drug maker said that it is currently negotiating its next-year’s basal insulin prices with pharmacy benefit managers (PBMs) and managed care organizations in the United States. These negotiations are expected to bring the prices, after rebates, lower than the company commanded in the US market during 2017.
While Novo Nordisk believes that market access for its key products will likely remain unchanged compared with 2017, the United States has what CEO Lars Fruergaard Jørgensen called “a tough competitive environment.” The company assured investors it was focusing on new products in order to reach its US financial growth targets, and cited the development of “innovative products within diabetes and obesity care” as an ongoing focus.
Rival drug maker, the France-based Sanofi, has already seen sales for its insulins (Lantus and Toujeo) erode by 23.9% due to competition from European biosimilars and US follow-on insulins such as Boehringer Ingelheim (BI)'s Basaglar.
In an attempt to slow that erosion from new competitors, Sanofi announced this week that it has filed a new patent infringement suit against Merck. The suit follows the FDA’s tentative approval of Merck’s insulin glargine follow-on (Lusduna) referenced on Lantus, and claims that Merck has violated 2 patents for the top-selling innovator insulin. The FDA cannot issue a final approval for Merck’s product until patent infringement litigation brought by Sanofi has concluded.
Novo Nordisk’s price negotiations and Sanofi’s legal maneuvers that attempt to retain market share for their products echo comments made by Steven B. Miller, MD, senior vice president and chief medical officer of the PBM Express Scripts, in a recent webinar hosted by Oncology Business Review. Miller said that he expects that innovator product manufacturers are “going to do everything they can to prevent loss of market share. We’ve already seen this with rituximab, so we see them bundling products together, offering different discounts, and doing all sorts of interesting deals in the marketplace to preserve their market share. I think they’re going to make it extremely hard for biosimilars to penetrate the market.” Even so, he noted that 5 companies are currently engaged in developing follow-ons to Lantus, with $5.6 billion in revenue potentially at stake.
As drug makers fight for a share of insulin profits, many clinicians are focused on seeing prices decline for the benefit of their patients. Robert Gabbay, MD, PhD, FACP, in a recent Peer Exchange™ panel discussion hosted by The American Journal of Managed Care®, said, “From the patient level, it’s, in some ways, a travesty, really. People with type 1 diabetes depend on insulin to stay alive, and the cost of insulin has skyrocketed over the last decade…Unfortunately, this is one of those situations where the patient loses in the end.”
However, Gabbay sees the potential for change ahead: “The good news is that there’s enough of an outcry around this, and it’s been documented, now, in a number of studies to show the plot of increasing insulin costs versus other drugs. We’re on the verge, I think, of seeing something happen to mitigate this issue.”
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Part 2: FDA Workshop Shares Manufacturer Perspective on the Value of Clinical Efficacy Testing
September 18th 2023Although removing the requirement for clinical efficacy testing for biosimilar approval would reduce development costs of biosimilars, representatives from several biosimilar manufacturers argued in the second day of the FDA’s development workshop that clinical outcomes will not be affected.
How Streamlining Development Can Save the US Biosimilar Industry
August 20th 2023On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.
Part 1: FDA Workshop Highlights Global Regulatory View on Biosimilar Development
September 13th 2023An FDA workshop featuring regulators from around the world provided the regulatory perspective on how each government determines whether a biosimilar is clinically equivalent to their reference product, highlighting the science behind their development guidelines.
AAM Report: Generics and Biosimilars Generate $408 Billion in 2022
September 12th 2023A report from the Association for Accessible Medicines (AAM) highlighted the value of biosimilars and generics, revealing that lower-cost versions of originator products accumulated $408 billion for the US health care system in 2022.
2 Clarke Drive
Cranbury, NJ 08512